首页> 外国专利> T CELL RECEPTOR KNOCK OUT ENGINEERED IMMUNE CELLS, ENDOWED WITH CHIMERIC ANTIGEN RECEPTORS BINDING TO CD123 FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LYMPHOMA OR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

T CELL RECEPTOR KNOCK OUT ENGINEERED IMMUNE CELLS, ENDOWED WITH CHIMERIC ANTIGEN RECEPTORS BINDING TO CD123 FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LYMPHOMA OR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

机译：T细胞受体敲除结合了CD123的嵌合抗原抗原受体的工程化免疫细胞，用于治疗复发/耐药的急性髓性淋巴瘤或塑性胞浆状树突状细胞瘤

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.

机译：本发明涉及表达针对CD123的嵌合抗原受体（CAR）的TCR KO-或TCR KO和dCK KO-工程改造的免疫细胞，该嵌合抗原是一种重组嵌合蛋白，能够将免疫细胞的特异性和反应性重定向至表达CD123的细胞，更特别地，其中细胞外配体结合是衍生自CD123单克隆抗体的scFV，赋予针对CD123阳性细胞的特异性免疫。赋予了这种CD123 CARs的工程免疫细胞特别适合于治疗难治性复发性AML和原始浆细胞样树突状细胞瘤，并可用作骨髓移植之前的治疗方法。

著录项

公开/公告号US2018051089A1

专利类型
公开/公告日2018-02-22

原文格式PDF
申请/专利权人 CELLECTIS;
展开▼

申请/专利号US201615546623
发明设计人 ROMAN GALETTO;BARBARA JOHNSON SASU;ARVIND RAJPAL;PHILIPPE DUCHATEAU;ALEXANDRE JUILLERAT;JULIEN VALTON;MATHIEU SIMON;
展开▼

申请日2016-01-25
分类号C07K16/28;A61K35/17;A61K39;C07K14/725;C07K16/30;C12N5;C12N5/0783;
国家 US
入库时间 2022-08-21 13:02:45

相似文献

专利
外文文献
中文文献